Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSV Vaccine in Adults ≥60 Years of Age

Next Previous
Trial Profile

A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSV Vaccine in Adults ≥60 Years of Age

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MVA-BN RSV (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms VANIR
  • Sponsors Bavarian Nordic

Most Recent Events

  • 24 Nov 2023 The trial has been completed in Germany (End Date: 01 Sep 2023), according to European Clinical Trials Database record.
  • 22 Jul 2023 According to Bavarian Nordic media release, this study did not meet all the primary endpoints hence company has announced to discontinue its RSV program, including its partnership with Nuance Pharma to develop and launch the vaccine for selected Asian markets.
  • 22 Jul 2023 Status changed from active, no longer recruiting to discontinued according to Bavarian Nordic media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top